

Spinal Muscular Atrophy (SMA)

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT04718181 BP42066

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The study is a randomized, single oral dose, crossover study in up to three parts to investigate the relative bioavailability and bioequivalence of two different formulations of risdiplam 5 mg (dispersible tablets) versus the current risdiplam oral solution formulation in healthy male and female participants. The effect of food on these two dispersible tablets and the current oral solution will be studied, as well as the effect of omeprazole on the dispersible tablets.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT04718181 BP42066
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years & ≤ 55 Years

Healthy Volunteers
Accepts Healthy Volunteers